UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Filed Pursuant to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report
(Date
of earliest event reported): April 28, 2010
Repros
Therapeutics Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-15281
|
76-0233274
|
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
2408
Timberloch Place, Suite B-7
The
Woodlands, Texas 77380
(Address
of principal
executive
offices
and
zip code)
|
|
|
(281)
719-3400
(Registrant’s
telephone number, including area code)
|
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
7.01 Regulation FD Disclosure.
The
disclosure in Item 8.01 below is incorporated into this Item 7.01 by
reference.
Item
8.01 Other Events.
On April
15, 2010, the Company issued a press release titled “Repros Announces Compliance
with NASDAQ Minimum Stockholders' Equity Requirement” related to the information
described in Item 3.01 of the Form 8-K filed on the same
date. Pursuant to a request from Nasdaq, the Company sets forth below
certain unaudited financial information on which it relied to believe it has met
the minimum stockholder equity requirement necessary to regain compliance with
Nasdaq's Marketplace Rules.
The
financial information provided below is unaudited as of the date of this report
and may change upon the Company's year-end audit.
|
Certain
unaudited balance sheet information as of April 26, 2010
|
|
|
Cash
and cash equivalents
|
|
$ |
4,027,875 |
|
|
Accounts
payable and accrued expenses
|
|
$ |
1,420,350 |
|
|
Stockholders'
equity
|
|
$ |
3,756,367 |
|
The
Company was able to increase its unaudited stockholders' equity through the sale
of shares of its common stock as a result of its ongoing offering of such shares
pursuant to the Equity Distribution Agreement between the Company and Ladenburg
Thalmann & Co. Inc. dated February 12, 2010. The Company notes
that continued listing on The Nasdaq Stock Market is contingent upon a
determination by NASDAQ that the Company has met all applicable continued
listing requirements.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
Repros
Therapeutics Inc. |
|
| |
|
|
| Date: April
28, 2010 |
|
|
|
| |
|
|
|
|
|
By:
|
/s/
Joseph S. Podolski |
|
| |
|
Joseph
S. Podolski |
|
| |
|
President
and Chief Executive Officer |
|